BIOMAT Database Logo BIOMAT Database Logo

Benign intracranial hypertension after topical steroid withdrawal. 1977

D T Fourie

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D009824 Ointments Semisolid preparations used topically for protective emollient effects or as a vehicle for local administration of medications. Ointment bases are various mixtures of fats, waxes, animal and plant oils and solid and liquid hydrocarbons. Ointment,Paste,Pastes,Salve,Unguent,Salves,Skin Ointment,Unguents,Ointment, Skin
D011559 Pseudotumor Cerebri A condition marked by raised intracranial pressure and characterized clinically by HEADACHES; NAUSEA; PAPILLEDEMA, peripheral constriction of the visual fields, transient visual obscurations, and pulsatile TINNITUS. OBESITY is frequently associated with this condition, which primarily affects women between 20 and 44 years of age. Chronic PAPILLEDEMA may lead to optic nerve injury (see OPTIC NERVE DISEASES) and visual loss (see BLINDNESS). Benign Intracranial Hypertension,Idiopathic Intracranial Hypertension,Intracranial Hypertension, Benign,Intracranial Hypertension, Idiopathic,Hypertension, Benign Intracranial,Hypertension, Idiopathic Intracranial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001623 Betamethasone A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724) Betadexamethasone,Flubenisolone,Celeston,Celestona,Celestone,Cellestoderm
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance

Related Publications

D T Fourie
Benign intracranial hypertension after withdrawal of topical steriods in an infant.
September 1976, British medical journal,
D T Fourie
Steroid-induced benign intracranial hypertension.
March 1981, Postgraduate medical journal,
D T Fourie
Benign intracranial hypertension following corticosteroid withdrawal in childhood.
September 1970, British medical journal,
D T Fourie
[Benign intracranial hypertension resulting from corticosteroid withdrawal: case report].
January 2002, No shinkei geka. Neurological surgery,
D T Fourie
Benign intracranial hypertension after minocycline therapy.
January 1978, European neurology,
D T Fourie
Benign intracranial hypertension after ciprofloxacin administration.
October 1990, Archives of disease in childhood,
D T Fourie
Benign intracranial hypertension after antibiotic therapy.
July 1972, British medical journal,
D T Fourie
[Benign intracranial hypertension after treatment with pefloxacin].
August 1998, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
D T Fourie
Topical steroid withdrawal and atopic dermatitis.
April 2024, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
D T Fourie
Benign intracranial hypertension.
April 1992, American family physician,
Copied contents to your clipboard!